Anti‐CD20 mAb maintenance therapy vs observation
Treatment‐related mortality · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy showed no clear difference in treatment‐related mortality compared with observation (low certainty).
1 finding from 1 review
- Risk ratio 0.82 [0.39, 1.71]4 studies · 1189 participantsLow